Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
SARS CoV 2 Infection: full-pipeline trial registry
12 of 36 indexed SARS CoV 2 Infection trials are currently recruiting.
Corpus placement: #419 of 28,707 conditions by registered trial count.
36 US clinical trials · 12 currently recruiting · #419 of 28,707 conditions by registered trial count
SARS CoV 2 Infection: 36 US clinical trials tracked, 12 recruiting.
SARS CoV 2 Infection is the subject of 36 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is BioNTech SE, running 6 of these trials.
Enrollment posture brief
Registry condition sars-cov-2-infection
OPEN 12 | RECR 33% | LATE 7 | EARLY 10 | RANK #419 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
SARS CoV 2 Infection lists 12 open slots (33% of 36 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for SARS CoV 2 Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
SARS CoV 2 Infection is recruiting below its size-band peers.
12 of 36 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates SARS CoV 2 Infection research.
BioNTech SE accounts for 6 of 36 trials (16.7%). 24 distinct sponsors appear on at least one study for this condition label.
-
Typical SARS CoV 2 Infection enrolment sits around 374 participants.
Median target enrolment is 374 among the 36 trials that report a genuine target (sentinel values excluded). 7 of those (19.4%) plan for fewer than 100 participants.
-
SARS CoV 2 Infection splits between interventional and observational designs.
22 interventional and 14 observational studies make up this index (61.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
36 total, page 1 of 1
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
BioNTech SE
NCT07300839
Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India
Boston University
NCT06168019
COVID-19 Transmission and Morbidity in Malawi
Boston University
NCT05973084
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
Columbia University
NCT05467930
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
University of Minnesota
NCT04910269
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Wes Ely
NCT06631287
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
NYU Langone Health
NCT05292274
Exercise in Child Health
University of California, Irvine
NCT05359991
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
Kara Chew
NCT06810934
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
Vanderbilt University Medical Center
NCT05421208
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
Vanderbilt University Medical Center
NCT07189936
T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients
Children's National Research Institute
NCT05141058
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
Medicago
NCT04636697
Understanding the Long-term Impact of COVID on Children and Families
NYU Langone Health
NCT05172011
Pediatric COVID Outcomes Study (PECOS)
Children's National Research Institute
NCT04830852
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
BioNTech SE
NCT07069309
Safety and Immunogenicity of NVX-CoV2705
Sanofi
NCT07079670
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
Novavax
NCT06633835
Post Acute Sequelae of COVID-19
Vanderbilt University Medical Center
NCT04964115
ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases
Columbia University
NCT05467917
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
BioNTech SE
NCT07222384
Transplacental Transmission of RSV (TTRSV)
Tulane University
NCT05443607
Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos
San Diego State University
NCT05697068
Cellular Senescence and COVID-19 Long-Hauler Syndrome
Mayo Clinic
NCT04903132
Pancoronavirus Vaccine Study in Healthy Adults
Duke University
NCT06950177
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
BioNTech SE
NCT04368728
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
BioNTech SE
NCT05004181
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
BioNTech SE
NCT05997290
Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake
Michigan State University
NCT04957082
COVID-19 SARS-CoV-2 RAST Study
Columbia University
NCT06452056
A Retrospective Study of COVID-19 Treatments
ProgenaBiome
NCT04949230
TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood
MiCo BioMed Co.
NCT05338762
Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)
University of Washington
NCT05074719
Safe and Healthy Schools
University of Wisconsin, Madison
NCT05105789
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
The University of Texas Health Science Center at San Antonio
NCT04818216
Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)
Johns Hopkins University
NCT04377672
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 6 |
| Phase 3 | 6 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on SARS CoV 2 Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on SARS CoV 2 Infection trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this SARS CoV 2 Infection page
36 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 SARS CoV 2 Infection trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- BioNTech SE sponsors the most SARS CoV 2 Infection trials on record, review their full trial history before evaluating a specific study. See BioNTech SE's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This SARS CoV 2 Infection condition card totals 36 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.